Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors

Lorena Incorvaia, Cinzia Ortega, Simon J. Crabb, Luca Galli, Riccardo Ricotta, Elena Verzoni, Roberto Iacovelli, Daniel Y. Heng, Cristina Masini, Marc R. Matrana, Francesco Carrozza, Liang Cheng, Camillo Porta, Sarah Scagliarini, Mimma Rizzo, Matteo Santoni, Alessandro Conti, Francesco Atzori, Sebastiano Buti, Maria Giuseppa VitaleGiulia Sorgentoni, Nuno Vau, Sara Merler, Alessia Cimadamore, Pierangela Sepe, Jeffrey Graham, Ugo De Giorgi, Francesco Massari, Alessandra Mosca, Erin Pierce, Vittorio Paolucci, Paolo Zucali, Giuseppe Fornarini, Giacomo Cartenì, Giuseppe Procopio, Nicola Battelli, Angelo Martignetti, Umberto Basso, Sergio Bracarda, Orazio Caffo, Marina Scarpelli, Antonio Lopez-Beltran, Franco Morelli, Fabio Calabrò, Michele Milella, Rodolfo Montironi, Daniele Santini, Alain Gelibter, Francesco Piva, Daniele Santini

Risultato della ricerca: Articlepeer review

Abstract

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second-or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second-or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses.The median PFS and OS of cabozantinib were 7.76 months (95% CI 6.51–10.88) and 11.57 months (95% CI 10.90–not reached (NR)) as second-line and 11.38 months (95% CI 5.79–NR) and NR (95% CI 11.51–NR) as third-line therapy. The median TTSF and OS were 11.57 and 15.52 months with the sequence of cabozantinib–nivolumab and 25.64 months and NR with nivolumab–cabozantinib, respectively. The difference between these two sequences was statistically significant only in good-risk patients. In the second-line setting, hemoglobin (Hb) levels (HR= 2.39; 95% CI 1.24–4.60, p = 0.009) and IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) group (HR = 1.72, 95% CI 1.04–2.87, p = 0.037) were associated with PFS while ECOG-PS (HR = 2.33; 95%CI, 1.16–4.69, p = 0.018) and Hb levels (HR = 3.12; 95%CI 1.18–8.26, p = 0.023) correlated with OS at multivariate analysis, while in the third-line setting, only Hb levels (HR = 2.72; 95%CI 1.04–7.09, p = 0.042) were associated with OS. Results are limited by the retrospective nature of the study.This real-world study provides evidence on the presence of prognostic factors in RCC patients receiving cabozantinib.
Lingua originaleEnglish
pagine (da-a)84-
Numero di pagine13
RivistaCancers
Volume12
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo